-
Mashup Score: 0Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials - 6 hour(s) ago
AbstractBackground. Relapse-free survival (RFS) has been considered a primary endpoint to assess the effects of immunotherapy in the adjuvant setting among
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy - 19 hour(s) ago
Abstract. Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1–mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Gene Fusion from Cancerous T Cells May Boost T-Cell Therapy - 8 day(s) ago
Incorporating a genetic change that cancerous T cells use to stay alive and grow may make T-cell therapies better cancer killers, a study in mice shows.
Source: www.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 37
A new drug could offer a powerful way to sensitise tumours to immunotherapy, a new trial suggests.
Source: www.icr.ac.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18
The microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma.
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 37
A new drug could offer a powerful way to sensitise tumours to immunotherapy, a new trial suggests.
Source: www.icr.ac.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Immunotherapy Combo Key to Treating Some Liver Tumors - 1 month(s) ago
Abstract: Combining the PD-L1 inhibitor durvalumab and the angiogenesis inhibitor bevacizumab with transarterial chemoembolization can prolong progression-free survival in patients with inoperable hepatocellular carcinoma. However, ongoing trials may reveal an even more effective combination of checkpoint inhibitor with VGEF inhibitors plus TACE therapy for patients with liver cancer.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 49FDA Approves Toripalimab for Advanced Nasopharyngeal Cancer - 2 month(s) ago
Adding toripalimab (Loqtorzi) to chemo extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.
Source: www.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Immunotherapy Combo Key to Treating Some Liver Tumors | Cancer Discovery News | American Association for Cancer Research - 2 month(s) ago
Abstract: Combining the PD-L1 inhibitor durvalumab and the angiogenesis inhibitor bevacizumab with transarterial chemoembolization can prolong progression-free survival in patients with inoperable hepatocellular carcinoma. However, ongoing trials may reveal an even more effective combination of checkpoint inhibitor with VGEF inhibitors plus TACE therapy for patients with liver cancer. DOI: https://doi.org/10.1158/2159-8290.CD-NB2024-0003 You do not currently have access to this content. Don’ t already
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 26Decoding the Autoantibody ‘Reactome’ in Cancer Immunotherapy | The Mark Foundation for Cancer Research - 2 month(s) ago
This project explores the diverse effects of autoantibodies on cancer immunotherapy outcomes, seeking to understand why patients respond so differently to treatment. Using a new antibody profiling…
Source: themarkfoundation.orgCategories: General Medicine News, Onc News and JournalsTweet
New meta-analysis in @JNCI_Now! A study by Sun Yat-sen University Cancer Center evaluated if relapse-free survival (RFS) is a valid surrogate for overall survival (OS) in adjuvant immunotherapy trials. #Immunotherapy Read here: https://t.co/6zhy0dCQtt https://t.co/jkMEUhup7M